Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Aflibercept Variable Dosing in nAMD, RVO, and DME (COVARIANT)
NCT03056079Phase 4Unknown
- Sponsor
- Unity Health Toronto
- Start
- Feb 2017
- Primary completion
- Feb 2024
- Modality
- Engineered Antibody Formats, Fc-Fusion Proteins
- Countries
- 1
01
Overview
A Phase 4 trial of aflibercept in neovascular age-related macular degeneration (NVAMD), diabetic macular edema (DME), retinal vein occlusion (RVO), sponsored by Unity Health Toronto. Status: unknown.
02
Drugs
aflibercept
03
Conditions
neovascular age-related macular degeneration (NVAMD)diabetic macular edema (DME)retinal vein occlusion (RVO)
Beyond the preview
Go deeper on NCT03056079.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03056079.